The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients
Abstract
Background: Reduced β‐glucocerebrosidase activity was observed in postmortem brains of both GBA1 mutation carrier and noncarrier Parkinson's disease patients, suggesting that lower β‐glucocerebrosidase activity is a key feature in the pathogenesis of PD. The objectives of this study were to confirm whether there is reduced β‐glucocerebrosidase activity in the CSF of GBA1 mutation carrier and noncarrier PD patients and verify if other lysosomal enzymes show altered activity in the CSF. Methods: CSF β‐glucocerebrosidase, cathepsin D, and β‐hexosaminidase activities were measured in 79 PD and 61 healthy controls from the BioFIND cohort. The whole GBA1 gene was sequenced. Results: Enzyme activities were normalized according to CSF protein content (specific activity). β‐glucocerebrosidase specific activity was significantly decreased in PD versus controls (‐28%, P < 0.001). GBA1 mutations were found in 10 of 79 PD patients (12.7%) and 3 of 61 controls (4.9%). GBA1 mutation carrier PD patients showed significantly lower β‐glucocerebrosidase specific activity versus noncarriers. β‐glucocerebrosidase specific activity was also decreased in noncarrier PD patients versus controls (‐25%, P < 0.001). Cathepsin D specific activity was lower in PD versus controls (‐21%, P < 0.001). β‐Hexosaminidase showed a similar trend. β‐Glucocerebrosidase specific activity fairly discriminated PD from controls (area under the curve, 0.72; sensitivity, 0.67; specificity, 0.77). A combination of β‐glucocerebrosidase, cathepsin D, and β‐hexosaminidase improved diagnostic accuracy (area under the curve, 0.77; sensitivity, 0.71; specificity, 0.85). Lower β‐glucocerebrosidase and β‐hexosaminidase specific activities were associated with worse cognitive performance. Conclusions: CSF β‐glucocerebrosidase activity is reduced in PD patients independent of their GBA1 mutation carrier status. Cathepsin D and β‐hexosaminidase were also decreased. The possible link between altered CSF lysosomal enzyme activities and cognitive decline deserves further investigation. © 2017 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Sevlever, D., Jiang, P., & Yen, S.-H. C. (2008) · Biochemistry · doi:10.1021/bi800699v · Cited by 305
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease
Pisani, V., Stefani, A., Pierantozzi, M., Natoli, S., Stanzione, P., Franciotta, D., & Pisani, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-188 · Cited by 158
Cited by
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673
Self-citationYang, Y., Yuan, Y., Zhang, G., Wang, H., Chen, Y.-C., Liu, Y., Tarolli, C. G., Crepeau, D., Bukartyk, J., Junna, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01932-x · Cited by 296
Czubowicz, K., Jęśko, H., Wencel, P., Lukiw, W. J., & Strosznajder, R. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1448-3 · Cited by 281
GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
Riboldi, G. M., & Di Fonzo, A. B. (2019) · Cells · doi:10.3390/cells8040364 · Cited by 274
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
Picca, A., Guerra, F., Calvani, R., Romano, R., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Biomolecules · doi:10.3390/biom11101508 · Cited by 189
Glycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
Exploring Sphingolipid Implications in Neurodegeneration
Alessenko, A. V., & Albi, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00437 · Cited by 141
Role of Sphingolipid Metabolism in Neurodegeneration
Alaamery, M., Albesher, N., Aljawini, N., Alsuwailm, M., Massadeh, S., Wheeler, M. A., Chao, C., & Quintana, F. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15044 · Cited by 129
Cosden, M., Jinn, S., Yao, L., Gretzula, C. A., Kandebo, M., Toolan, D., Hatcher, N. G., Ma, L., Lemaire, W., Adam, G. C., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105507 · Cited by 23
Metadata
- Authors
- Parnetti, L., Paciotti, S., Eusebi, P., Dardis, A., Zampieri, S., Chiasserini, D., Tasegian, A., Tambasco, N., Bembi, B., Calabresi, P., & Beccari, T.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2017-08-26
- Volume
- 32
- Issue
- 10
- Pages
- 1423-1431
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2749037114
- Cited by
- 178
- References
- 3
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.